Latest Insider Transactions at Cardiff Oncology, Inc. (CRDF)
This section provides a real-time view of insider transactions for Cardiff Oncology, Inc. (CRDF). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cardiff Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cardiff Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2023
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
30,000
+4.12%
|
$30,000
$1.37 P/Share
|
|
Nov 25
2022
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+29.0%
|
$10,000
$1.43 P/Share
|
|
Sep 19
2022
|
Lale White Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+11.65%
|
$15,000
$1.64 P/Share
|
|
Sep 16
2022
|
James O Armitage Director |
BUY
Open market or private purchase
|
Indirect |
13,000
+50.0%
|
$13,000
$1.56 P/Share
|
|
Sep 16
2022
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+33.33%
|
$30,000
$1.56 P/Share
|
|
Sep 15
2022
|
Renee P Tannenbaum Director |
BUY
Open market or private purchase
|
Direct |
10,000
+38.24%
|
$10,000
$1.72 P/Share
|
|
Sep 15
2022
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
150,000
+18.87%
|
$150,000
$1.71 P/Share
|
|
Jul 05
2022
|
Lale White Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
28,858
+22.61%
|
$57,716
$2.6 P/Share
|
|
Sep 21
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
30,000
+5.72%
|
$180,000
$6.75 P/Share
|
|
Sep 10
2021
|
James E. Levine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+29.52%
|
$180,000
$6.48 P/Share
|
|
Mar 26
2021
|
Rodney S Markin Director |
BUY
Open market or private purchase
|
Indirect |
2,900
+10.83%
|
$29,000
$10.32 P/Share
|
|
Mar 23
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
10,000
+0.72%
|
$100,000
$10.24 P/Share
|
|
Mar 23
2021
|
Mark Erlander Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
965
+6.25%
|
$9,650
$10.34 P/Share
|
|
Mar 23
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Open market or private purchase
|
Direct |
960
+13.69%
|
$9,600
$10.31 P/Share
|
|
Mar 23
2021
|
Gary S Jacob |
BUY
Open market or private purchase
|
Direct |
2,370
+5.12%
|
$23,700
$10.41 P/Share
|
|
Mar 22
2021
|
John P Brancaccio |
BUY
Open market or private purchase
|
Direct |
3,000
+19.66%
|
$30,000
$10.95 P/Share
|
|
Mar 19
2021
|
James O Armitage Director |
BUY
Open market or private purchase
|
Direct |
4,000
+21.63%
|
$40,000
$10.82 P/Share
|
|
Mar 18
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
3,000
+0.33%
|
$30,000
$10.56 P/Share
|
|
Mar 04
2021
|
Gary W Pace Director |
BUY
Open market or private purchase
|
Direct |
1,500
+0.33%
|
$13,500
$9.27 P/Share
|
|
Jan 02
2021
|
Mark Erlander Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
113
-0.83%
|
-
|
|
Jan 02
2021
|
Mark Erlander Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
260
+1.87%
|
-
|
|
Jan 02
2021
|
Vicki Kelemen Exec. VP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
31
-0.61%
|
-
|
|
Jan 02
2021
|
Vicki Kelemen Exec. VP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
70
+1.35%
|
-
|
|
Nov 23
2020
|
Vicki Kelemen Exec. VP and COO |
SELL
Open market or private sale
|
Direct |
35,321
-87.48%
|
$635,778
$18.6 P/Share
|
|
Nov 23
2020
|
Vicki Kelemen Exec. VP and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,321
+46.66%
|
$70,642
$2.48 P/Share
|